Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In-vivo evaluation over 16 week DMBA/croton oil tumor induced mice model showed noteworthy tumor targeting with down regulation of overexpressed COX-2, cytokines and nuclear factors on western blot analysis.
|
31761163 |
2020 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Microarray analysis of tumor xenograft tissue showed cyclooxygenase-2 expression as a potential biomarker for the efficacy of such combination therapy.
|
31692172 |
2020 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In summary, the location and type of Nos2<sup>high</sup> cells, NO flux, and the inflammatory status of other cells, such as Cox2<sup>high</sup> cells in the tumor niche contribute to Nos2 inflammatory mechanisms that promote disease progression of 4T1 tumors.
|
31683257 |
2020 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In our colorectal cancer cohort, tumor tissue presents a differential COX-2 expression pattern with lower enzymatic activity that can be related to an altered metabolic and proteomic profile.
|
30700940 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The co-expression of PTGS2 gene and M2 markers in human thyroid carcinoma highlights the possibility to counteract tumor growth through COX-2 inhibition.
|
31113465 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
COX-2 and proliferating cell nuclear antigen (PCNA) expression were assessed immunohistochemically. lncRNA-CCHE1 expression was upregulated in CRC tissues compared to adjacent non-cancerous tissues, and was significantly associated with larger tumor size, less differentiated histology, advanced dukes' stage, positive lymph node involvement and vascular invasion.
|
30484108 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
There was an elevated expression of the immunosuppressive genes PTGS2 (encoding COX-2) and CD274 (encoding PD-L1) in human and murine claudin-low tumors.
|
31366361 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This study demonstrates the association of gastric acid stress with Cyclooxygenase-2-dependent tumor formation originating from tumor-competent Krt5<sup>+</sup>/Krt15<sup>+</sup> foregut basal progenitor cells.
|
31110179 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Because the association between T cell infiltration and the EPHA2/TGF-β/COX-2 axis is supported by independent clinical data, these results provide a rationale for ensuing clinical trials aimed at incorporating pancreatic cancer into the range of immunotherapy-responsive tumors.
|
31355777 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In MCF-7/ADR tumor-bearing nude mice, HPPDC nanoparticles showed excellent tumor-targeting ability, remarkably enhanced tumor chemosensitivity and reduced COX-2 and P-gp expressions in tumor tissues.
|
31623608 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
COX-2 expression was only significantly correlated with the tumor stage.
|
30638861 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
So far, several studies have proposed different targets such as cyclooxygenase-2 (COX-2), some toll-like receptors (TLRs), mitogen-activated protein kinases (MAPKs) etc., for the amelioration of radiation toxicity and enhancing tumor response.
|
30318012 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical results showed that the positive expression rates of COX-2 and MMP-13 in gastric cancer tissues were 76.25% (60/80) and 71.25% (57/80), respectively and the high expression was related to the invasion, metastasis and tumor stage.
|
30003735 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
High COX-2 immunostaining is an independent predictor of higher tumor grade (<i>p</i> < 0.001), muscle invasion (<i>p</i> = 0.015), advanced pathological T (<i>p</i> = 0.014), lymphovascular invasion (<i>p</i> = 0.011), and distant metastasis (<i>p</i> = 0.039).
|
31179232 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
COX-2 is frequently overexpressed in tumors and increases tumor invasiveness and angiogenesis.
|
30715649 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cyclooxygenase 2 is widely expressed in various cancer cells and participates in the occurrence and development of tumors by regulating a variety of downstream signaling pathways.
|
31822119 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
MTA1 overexpression resulted in the death of all mice at 30 days after tumor inoculation and upregulated the expression of COX-2, Ang1/2, HIF-1a and VEGF, which were down-regulated by MTA1 silencing.
|
30651530 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Finally, we demonstrate that STAT3 deletion and JAK/STAT inhibition in macrophages increases expression of the protumorigenic factor cyclooxygenase-2 (COX-2), and that COX-2 inhibition enhances responsiveness of tumors to ruxolitinib.
|
31147469 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Tumor-supplied IL1β contributes to adipocyte lipolysis and regulates a proinflammatory phenotype in adipocytes via upregulation of COX-2 and MCP-1.
|
31562254 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The correlations of COX-2 expression with tumor clinicopathological variables and overall survival were analyzed.
|
31114336 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical results showed that the positive expression rates of COX-2 and MMP-13 in gastric cancer tissues were 76.25% (60/80) and 71.25% (57/80), respectively and the high expression was related to the invasion, metastasis and tumor stage.
|
30941969 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In the animal experiments, IATL reduced the size and weight of glioma tumors in xenograft mice and inhibited the expression of COX-2 and phosphorylated NF-κB p65 in the transplanted tumors.
|
30740911 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The association of tumour PTGS2 (COX-2) expression with colorectal cancer mortality is stronger in BRAF-mutated tumours than in BRAF-wild-type tumours, supporting interactive roles of PTGS2 (COX-2) expression and BRAF mutation statuses in prognostication of patients with colorectal cancer; ClinicalTrials.gov Identifier, NCT00003835.
|
30826660 |
2019 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Celecoxib use during chemotherapy adversely affected survival in patients with breast cancer, and the effect was more marked in PTGS2-low and/or estrogen receptor-negative tumors.
|
30702971 |
2019 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Instead, cyclooxygenase 2 expression increases with tumor extension while MIB1 expression is not associated with tumor size.
|
31291992 |
2019 |